Anti Mitochondrial Antibody IFA Titres near me in Ernakulam
Understanding Anti Mitochondrial Antibody IFA Titres in Ernakulam
What is Anti Mitochondrial Antibody IFA Titres in Ernakulam?
The Anti Mitochondrial Antibody IFA Titres is a blood test used to measure the amount of antibodies (titre) directed against mitochondria, the energy-producing structures within cells. This test helps diagnose autoimmune liver diseases, particularly primary biliary cholangitis (PBC), distinguishing it from other liver conditions such as autoimmune hepatitis, primary sclerosing cholangitis, and viral hepatitis. It is available at an affordable price with Tata 1mg labs in Ernakulam.
This test may be recommended if symptoms of liver disease such as fatigue, itching, jaundice, and abnormal liver function tests (particularly alkaline phosphatase) are noticed. It may also be done for individuals with risk factors such as a family history of autoimmune liver diseases or other autoimmune disorders. Additionally, the Anti Mitochondrial Antibody-IFA test can be used to monitor the progression of PBC and the response to treatment.
An overnight fasting (8 to 12 hours) is preferred before getting this test done, however it is not mandatory.
What does Anti Mitochondrial Antibody IFA Titres measure?
The Anti Mitochondrial Antibody IFA Titres measures the amount of anti-mitochondrial antibodies (AMAs) that play a critical role in the context of primary biliary cholangitis (PBC), a chronic liver disease. These autoantibodies target specific proteins in the mitochondria and are found in approximately 95% of individuals suffering from PBC, making them highly specific for the disease.
PBC most often develops during middle age and is usually seen in individuals between the ages of 35 and 60, and most individuals have no specific symptoms. The disease is often discovered incidentally due to abnormal results on routine liver blood tests. Once PBC is suspected, an Anti Mitochondrial Antibody IFA Titres is used to check for antimitochondrial antibodies (AMA). Identifying AMAs early in the disease process enables doctors to initiate treatments such as ursodeoxycholic acid, which can slow disease progression, reduce liver damage, and improve symptoms like fatigue and itching. Early detection also helps prevent complications such as cirrhosis and liver failure. Additionally, it enables patients to adopt lifestyle changes and receive regular monitoring, which further contributes to better long-term health outcomes and quality of life.